Search This Blog

Friday, June 28, 2019

FDA OKs Retrophin’s Thiola for cystinuria

The FDA approves Retrophin’s (NASDAQ:RTRX) enteric coated Thiola EC (tiopronin) for the treatment of a rare inherited disorder called cystinuria (high levels of the amino acid cysteine in the urine) that leads to kidney stones.
Commercial launch will commence in July.
Shares are up 3% after hours.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.